Krebs Biochemicals to Merge with Ipca Laboratories

Krebs Biochemicals & Industries Ltd announced that its Board of Directors has approved a Scheme of Amalgamation with Ipca Laboratories Limited. The merger, subject to regulatory approvals, is set to take effect from April 1, 2026. The rationale includes achieving operational synergies, cost optimization, and consolidating businesses. Krebs Biochemicals, which has incurred continuous losses, possesses manufacturing capabilities for fermentation-based APIs that Ipca Laboratories lacks, potentially enabling Ipca to develop new APIs and secure supply chains for key intermediates. The transaction is considered a related party transaction but will be conducted at arm's length. No cash consideration will be paid; Ipca will issue 7 equity shares for every 200 shares of Krebs Biochemicals.